EVALUATION AND ANALYSIS OF THE INVOLVEMENT OF A FIBRINOLYSIS INHIBITOR OF THE COAGULATION SYSTEM IN THE PROGRESSION OF CORONARY HEART DISEASE CHD
26.03.2023
International Scientific Journal "Science and Innovation". Series D. Volume 2 Issue 3
Nurillaeva Nargiza, Zоkirova Mubarakkhon, Khasanova Nargiza
Abstract. Thrombin-activated Fibrinolysis inhibitor (TAFI), participates in the regulation of the balance between coagulation and fibrinolysis. High plasma levels of TAFI may therefore contribute to a hyperfibrinolytic condition and an increased risk of thrombotic disorders. Coronary stenosis is a consequence of the progression of atherosclerotic plaques, which is associated with a violation of fibrinolysis. Thrombin-activated fibrinolysis inhibitor (TAFI) and plasminogen activator 1 inhibitor (PAI-1) are fibrinolysis inhibitors whose levels depend on acquired conditions and polymorphisms. Therefore, our study is aimed at studying the association of TAFI gene polymorphism with the severity of coronary stenosis in patients with stable coronary artery disease (CAD).
The methods that have recently appeared for determining alleles of polymorphic genetic markers using polymerase chain reaction will allow us to assess the genetic risk of developing cardiovascular pathology especially for the purpose of primary prevention of coronary heart disease, as well as to improve new approaches to individualization of therapy as a secondary prevention of the disease.
Keywords: cardiovascular disease, ischemic heart disease, risk factors for the development of cardiovascular disease, myocardial infarction, t-PA - tissue plasminogen activator; TAFI, thrombin-activated fibrinolytic inhibitor; TAFIa is a thrombin-activated fibrinolytic inhibitor
References:
1. Townsend N. Cardiovascular disease in Europe: epidemiological update 2016.
2. Boffa M.B., Reid T.S., Joo E., Nesheim M.E., Koschinsky M.L. Characterization of the gene encoding human TAFI. Thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B) //Biochemistry.-38.-1999.- P. 6547- 6558.
3. Зокирова М.Б. Зависимость повышенной концентрации TAFI с сердечно-сосудистым риском. //XI Международный конгресс «Кардиология на перекрестке наук» 2021г. [Zokirova M.B. Zavisimost' povyshennoy kontsentratsii TAFI s serdechno-sosudistym riskom. XI Mezhdunarodnyy kongress «Kardiologiya na perekrestke nauk» 2021g].
4. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells //Nucleic Acid Res.16.-1988.-1215].
5. M. Henry, H. Aubert, P.E. Morange, I. Nanni, Marie-Christine Alessi, L.Tiret, I.Juhan-Vague. Identification of polymer-phisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled //Blood (2001) 97 (7): 2053–2058. https://doi.org/10.1182/blood.V97.7.2053
6. Нуриллаева Н.М., Оценка взаимосвязанного влияния полиморфизма генов системы гемостаза и доминирующих факторов риска на раннюю манифестацию ишемической болезни сердца. //Евразийский Союз Ученых (ЕСУ) № 4 (13), 2015 | Медицинские науки. Стр 142-145 [Nurillayeva N.M., Otsenka vzaimosvyazannogo vliyaniya polimorfizma genov sistemy gemostaza i dominiruyushchikh faktorov riska na rannyuyu manifestatsiyu ishemicheskoy bolezni serdtsa. Yevraziyskiy Soyuz Uchenykh (YESU) № 4 (13), 2015 | Meditsinskiye nauki. Str 142-145]
7. Nick Townsend, Lauren Wilson, Prachi Bhatnagar, Kremlin Wickramasinghe , Mike Rayner , Melanie Nichols //https://www.ncbi.nlm.nih.gov/Cardiovascular disease in Europe: epidemiological update 2016. //www.ncbi.nlm.nih.gov/https://www.altmetric.com/details/10514271
8. https://news.un.org/ru/story/2021/01/1394212, WHO,2017
9. https://podrobno.uz/cat/obchestvo/neuteshitelnaya-statistika-chislo-serdechno-sosudistykh-zabolevaniy-v-uzbekistane-za-5-let-vyroslo-n.
10. Zоkirova Mubarakkhon – To study the involvement of a fibrinolysis inhibitor of the coagulation system in the progression of coronary heart disease CHD //New Day in Medicine 12(50)2022 198-205 https://newdaymedicine.com/index.php/2022/12/26 Entered 10.01.2023
![](images/google_scholar.png)
![](images/cyberleninka_logo.png)